Research
Hormonal
Among GLP-1/GIP agonists used in Type 1 Diabetes, tirzepatide produces significantly greater weight loss (10.9%) compared to semaglutide (9.9%) and liraglutide (7.1%).
If you have Type 1 Diabetes and obesity, tirzepatide appears to offer the highest weight loss potential (approx. 11%) compared to semaglutide (approx. 10%) and liraglutide (approx. 7%) over 12 months, though all are effective.
ModerateSupportsMEDIUM confidence
Tirzepatide showed the greatest reduction of weight loss (10.9%; p < 0.001), followed by semaglutide (9.9%; p < 0.001) and liraglutide (7.1%; p < 0.001).
Why this rating
Real-world observational data with propensity score matching, but unequal sample sizes (n=35 for tirzepatide vs n=97 for liraglutide).
Source
Weight loss in people with type 1 diabetes over 12 months: Real‐world data comparing tirzepatide, semaglutide and liraglutide
Ebaa Al‐Ozairi et al. · Diabetes Obesity and Metabolism · 2025
DOI 10.1111/dom.70172
cohort · n=250Cited 6×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- In adults with Type 1 Diabetes (T1D) and obesity (BMI ≥27 kg/m²), 12 months of treatment with GLP-1 receptor agonists (tirzepatide, semaglutide, or liraglutide) produces significant weight loss (7.1%–10.9%) without increasing the risk of severe hypoglycemia or diabetic ketoacidosis (DKA).Moderate
- GLP-1/GIP agonists reduce daily insulin requirements in Type 1 Diabetes patients by 8.3 to 11.4 units per day over 12 months, likely due to reduced insulin resistance.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →